Pimurutamab
As of the edition of 20 October 2026, Pimurutamab is an antibody: in active development; acts on EGFR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 15, 0 stopped early
- Disease areas
- Cancer; Digestive system; Ear, nose and throat; Lungs and airways; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EGFR | Epidermal growth factor receptor | P00533 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 0 |
| Phase 2 | 12 | 1 | 3 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 15 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Henlix | Lead sponsor of trials | 2016 to now |
| Henlius Biotech | Lead sponsor of trials | 2018 to now |